Source:http://linkedlifedata.com/resource/pubmed/id/21300825
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2011-3-3
|
pubmed:abstractText |
Inflammatory cytokines modulate immune responses in the tumor microenvironment during progression/metastasis. In this study, we have assessed the role of IL-1 and IL-17 in the control of antitumor immunity versus progression in a model of experimental lung metastasis, using 3LL and B16 epithelial tumor cells. The absence of IL-1 signaling or its excess in the lung microenvironment (in IL-1? and IL-1R antagonist knockout [KO] mice, respectively) resulted in a poor prognosis and reduced T cell activity, compared with WT mice. In IL-1? KO mice, enhanced T regulatory cell development/function, due to a favorable in situ cytokine network and impairment in APC maturation, resulted in suppressed antitumor immunity, whereas in IL-1R antagonist KO mice, enhanced accumulation and activity of myeloid-derived suppressor cells were found. Reduced tumor progression along with improved T cell function was found in IL-17 KO mice, compared with WT mice. In the microenvironment of lung tumors, IL-1 induces IL-17 through recruitment of ?/? T cells and their activation for IL-17 production, with no involvement of Th17 cells. These interactions were specific to the microenvironment of lung tumors, as in intrafootpad tumors in IL-1/IL-17 KO mice, different patterns of invasiveness were observed and no IL-17 could be locally detected. The results highlight the critical and unique role of IL-1, and cytokines induced by it such as IL-17, in determining the balance between inflammation and antitumor immunity in specific tumor microenvironments. Also, we suggest that intervention in IL-1/IL-17 production could be therapeutically used to tilt this balance toward enhanced antitumor immunity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1550-6606
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
186
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3462-71
|
pubmed:meshHeading |
pubmed-meshheading:21300825-Animals,
pubmed-meshheading:21300825-Carcinoma, Lewis Lung,
pubmed-meshheading:21300825-Cell Communication,
pubmed-meshheading:21300825-Cell Line, Tumor,
pubmed-meshheading:21300825-Immune Tolerance,
pubmed-meshheading:21300825-Inflammation Mediators,
pubmed-meshheading:21300825-Interleukin-17,
pubmed-meshheading:21300825-Interleukin-1beta,
pubmed-meshheading:21300825-Lung Neoplasms,
pubmed-meshheading:21300825-Male,
pubmed-meshheading:21300825-Melanoma, Experimental,
pubmed-meshheading:21300825-Mice,
pubmed-meshheading:21300825-Mice, Inbred C57BL,
pubmed-meshheading:21300825-Mice, Knockout,
pubmed-meshheading:21300825-Neoplasm Invasiveness
|
pubmed:year |
2011
|
pubmed:articleTitle |
Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis.
|
pubmed:affiliation |
Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and National Institute of Biotechnology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|